These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 22623362)
1. Influence of fourth generation poly(propyleneimine) dendrimers on blood cells. Ziemba B; Halets I; Shcharbin D; Appelhans D; Voit B; Pieszynski I; Bryszewska M; Klajnert B J Biomed Mater Res A; 2012 Nov; 100(11):2870-80. PubMed ID: 22623362 [TBL] [Abstract][Full Text] [Related]
2. In vivo toxicity of poly(propyleneimine) dendrimers. Ziemba B; Janaszewska A; Ciepluch K; Krotewicz M; Fogel WA; Appelhans D; Voit B; Bryszewska M; Klajnert B J Biomed Mater Res A; 2011 Nov; 99(2):261-8. PubMed ID: 21976451 [TBL] [Abstract][Full Text] [Related]
3. The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI. Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Voit B; Szewczyk M; Góra-Tybor J; Robak T; Klajnert B; Bryszewska M Mol Pharm; 2013 Jun; 10(6):2490-501. PubMed ID: 23641871 [TBL] [Abstract][Full Text] [Related]
4. Genotoxicity of poly(propylene imine) dendrimers. Ziemba B; Matuszko G; Appelhans D; Voit B; Bryszewska M; Klajnert B Biopolymers; 2012 Aug; 97(8):642-8. PubMed ID: 22605555 [TBL] [Abstract][Full Text] [Related]
5. Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer. Ziemba B; Franiak-Pietryga I; Pion M; Appelhans D; Muñoz-Fernández MÁ; Voit B; Bryszewska M; Klajnert-Maculewicz B Int J Pharm; 2014 Jan; 461(1-2):391-402. PubMed ID: 24361266 [TBL] [Abstract][Full Text] [Related]
6. Poly(propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity. Drzewińska J; Appelhans D; Voit B; Bryszewska M; Klajnert B Biochem Biophys Res Commun; 2012 Oct; 427(1):197-201. PubMed ID: 22995301 [TBL] [Abstract][Full Text] [Related]
7. Interactions between U-937 human macrophages and poly(propyleneimine) dendrimers. Kuo JH; Jan MS; Lin YL J Control Release; 2007 Jul; 120(1-2):51-9. PubMed ID: 17537537 [TBL] [Abstract][Full Text] [Related]
8. The influence of maltose modified poly(propylene imine) dendrimers on hen egg white lysozyme structure and thermal stability. Ciolkowski M; Pałecz B; Appelhans D; Voit B; Klajnert B; Bryszewska M Colloids Surf B Biointerfaces; 2012 Jun; 95():103-8. PubMed ID: 22410344 [TBL] [Abstract][Full Text] [Related]
10. Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays. Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Maciejewski H; Voit B; Kaczmarek A; Robak T; Klajnert-Maculewicz B; Cebula-Obrzut B; Smolewski P; Borowiec M; Bryszewska M Anticancer Agents Med Chem; 2017; 17(1):102-114. PubMed ID: 27349446 [TBL] [Abstract][Full Text] [Related]
11. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Gupta U; Dwivedi SK; Bid HK; Konwar R; Jain NK Int J Pharm; 2010 Jun; 393(1-2):185-96. PubMed ID: 20382210 [TBL] [Abstract][Full Text] [Related]
12. Influence of different generations of poly(propylene imine) dendrimers on human erythrocytes. Mishra V; Gupta U; Jain NK Pharmazie; 2010 Dec; 65(12):891-5. PubMed ID: 21284258 [TBL] [Abstract][Full Text] [Related]
13. Interaction study between maltose-modified PPI dendrimers and lipidic model membranes. Wrobel D; Appelhans D; Signorelli M; Wiesner B; Fessas D; Scheler U; Voit B; Maly J Biochim Biophys Acta; 2015 Jul; 1848(7):1490-501. PubMed ID: 25843678 [TBL] [Abstract][Full Text] [Related]
14. Dendrimer-based nanoparticles for potential personalized therapy in chronic lymphocytic leukemia: Targeting the BCR-signaling pathway. Franiak-Pietryga I; Maciejewski H; Ostrowska K; Appelhans D; Voit B; Misiewicz M; Kowalczyk P; Bryszewska M; Borowiec M Int J Biol Macromol; 2016 Jul; 88():156-61. PubMed ID: 26987432 [TBL] [Abstract][Full Text] [Related]
15. Influence of dendrimers on red blood cells. Ziemba B; Matuszko G; Bryszewska M; Klajnert B Cell Mol Biol Lett; 2012 Mar; 17(1):21-35. PubMed ID: 22086186 [TBL] [Abstract][Full Text] [Related]
16. Investigations on biodistribution of technetium-99m-labeled carbohydrate-coated poly(propylene imine) dendrimers. Agashe HB; Babbar AK; Jain S; Sharma RK; Mishra AK; Asthana A; Garg M; Dutta T; Jain NK Nanomedicine; 2007 Jun; 3(2):120-7. PubMed ID: 17572354 [TBL] [Abstract][Full Text] [Related]
17. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Kesharwani P; Tekade RK; Jain NK Biomaterials; 2014 Jul; 35(21):5539-48. PubMed ID: 24731713 [TBL] [Abstract][Full Text] [Related]
18. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Kesharwani P; Tekade RK; Jain NK Nanomedicine (Lond); 2014 Oct; 9(15):2291-308. PubMed ID: 24593000 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. Stasko NA; Johnson CB; Schoenfisch MH; Johnson TA; Holmuhamedov EL Biomacromolecules; 2007 Dec; 8(12):3853-9. PubMed ID: 18004811 [TBL] [Abstract][Full Text] [Related]
20. Interaction of heme proteins with poly(propyleneimine) dendrimers in layer-by-layer assembly films under different pH conditions. He P; Li M; Hu N Biopolymers; 2005 Dec; 79(6):310-23. PubMed ID: 16127662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]